Clinical trials for better health policies

©Mario Beauregard/Fotolia.com

A recent OECD Recommendation on the Governance of Clinical Trials issued in December 2012 could improve the outlook for fighting deadly diseases around the world. Here is how.

Chronic myelogenous leukemia (CML) is a rare cancer that affects the bone marrow. Until ten years ago, a diagnosis of CML was a death sentence unless you had a tissue-matched donor, usually a sibling, and underwent a bone marrow transplant. In 1996, laboratory scientists showed that a drug selectively killed CML cells in culture without harming normal cells. Two years later, the first reports of 31 patients treated with this drug were published; all had dramatic responses.

This impressive progress changed the outlook for these patients, and it could not have been made without clinical trials. And with life expectancy rising around the world, but haunted by the prospect of substantial disability, such clinical trials are likely to become more important in the years ahead. But they are not without their challenges.

Recently the OECD adopted a policy initiative on the governance of clinical trials in an attempt to define a new framework for better oversight of clinical trials, with a special emphasis on facilitating those trials that have public and charitable rather than industry funders.* Why was the instrument adopted and what can it help to achieve?

A tale of two studies

Clinical trials are rigorously designed experiments in which participants who have consented to receive a new therapy or to be assigned randomly to one of several possible treatments are carefully studied for the positive and negative effects of those therapies. The aim is to provide sufficient evidence to guide medical practice and public health policy. Clinical trials are a critical step for the production of new drugs and for the study of existing health treatments. They improve the health and quality of life of our citizens, add value to our economies, and guide policymakers responsible for laws and regulations. This benefit applies to both common and rare diseases.

Take the promising results related to CML again. Over the subsequent five years, multiple studies confirmed the efficacy of the drug, now called Gleevec™. In 2013, bone marrow transplantation is rarely required for patients with CML, whose extended survival is expected. How did this happen? University medical scientists supported by US taxpayer funds from the National Institutes of Health (NIH) worked with a pharmaceutical company, Novartis, to take this drug from the shelf to the clinic. Now patients all over the world receive Gleevec™. Its approval came about because of rigorously conducted clinical trials in which participants with CML agreed to receive an experimental, untested drug. They took significant risks because no one knew whether the drug would work or have bad side effects. Later trials have included Gleevec™ as one of multiple therapies; participants are taking much less risk because the effects of the drugs are now well-known. But because CML is rare, international studies were essential to carry out the test on enough patients to get significant results.

More common diseases also benefit from clinical trials. About the same time that Gleevec™ studies began, 3,234 healthy people at high risk of developing type 2 diabetes agreed to take part in a clinical trial to see if their diabetes could be prevented. A third of the patients had no treatment, a third received an approved marketed anti-diabetes drug called metformin, and the remaining third were put on diet and exercise programmes. Four years later, the people who changed their diet and took exercise were found to be only half as likely to develop diabetes as those with no treatment. Metformin reduced the likelihood of developing diabetes, but also provided less benefit than diet and exercise. The study was funded by US taxpayers and conducted at 27 different sites.

Worldwide, about 370 million people have type 2 diabetes; the WHO estimates that this will rise to 552 million by 2030. Could the results of the US study apply elsewhere, in Germany and the UK, or India and South Africa, for instance? Clinical trials in these countries could help us find out.

The question is, how can we harmonise approaches and better compare results for better policies? Every country has laws and regulations governing the conduct of clinical trials. Following the Second World War, all nations adopted some basic principles to guide the ethical conduct of research. International guidelines are detailed in the Nuremberg Code and the Declaration of Helsinki, while many countries have additional reports, such as the Belmont Report in the US, that outline common principles (see references). These are codified and implemented differently in different countries and regions, but the common principles apply in all countries.

While research studies may pose risks to participants, failure to conduct research poses much greater risks to citizens everywhere. Examples of treatments introduced without enough evidence include thalidomide, which caused disastrous birth defects in infants when given to pregnant women; administration of high doses of oxygen to premature infants with consequent blindness; and the use first of radical mastectomy and, later, of bone marrow transplantation for breast cancer, with major toxicity and no benefit.

Because of differences in laws and regulations, there are often barriers to conducting international research. Regulations designed to assign responsibility for protection of participants and ensure accountability may hinder collaboration. Not all clinical trials pose similar risks to participants. Treatments that are untested may create significant risks to participants and liability for sponsors. In contrast, trials of established therapies (as in the case of the diabetes study described above) pose little or no risk to participants. Existing regulatory systems often have similar administrative requirements whatever the risk, and sponsor liability may be significant.

What is the new OECD Recommendation about? Health care systems and clinical research infrastructure vary widely, especially between high income and lower income countries. Many policy barriers to conducting international trials may exist, many deriving from inconsistencies in definitions, assignment of responsibilities and requirements for oversight. The OECD initiative is a major step towards developing a harmonised framework for the governance of clinical trials. It introduces a risk-based oversight and management methodology, which combines risk categories based on the marketing authorisation status of the medical product with a trial-specific approach that considers issues such as the type of populations involved in a trial, and the informed consent of the patients.

In other words, besides facilitating the conduct of international trials, the implementation of the OECD Recommendation helps to streamline procedures for low-risk trials, while at the same time strengthening the protection of the patients, increasing the quality of the data and improving the credibility of the results. It also addresses the thorny challenge of seeking an accepted method for assessing the risk that participants face in entering a trial, and hence the responsibility borne by the study sponsor for compensation and care of participants affected by the study.

In this together

In December 2012, The Lancet published an entire issue on the Global Burden of Disease Study, demonstrating improved life expectancy with substantial disability for the last decade in most countries. Neither the quality of life nor our global economy can afford to continue these trends.

Indeed, science, health care and disease are now shared globally. Biomedical research is resource-intensive. Evidence gathered in one country is used in others, sometimes without adequate study. Especially for diseases in which large numbers of participants and locations are needed to answer scientific questions with statistical validity, international studies are essential. In rare diseases, it is impossible to do studies in single countries. An outstanding example is the development of arsenic trioxide for acute promyelocytic leukemia, a treatment discovered in China, studied worldwide and now benefiting patients on every continent. Regardless of economic resources, all countries should participate in joint scientific enterprises to ensure maximal benefit.

The OECD recommendations are designed to facilitate collaboration, leverage existing investments, and enable all nations to improve the health of their citizens and economies, enhancing technological development while prolonging healthier, more productive, lives.

References

The 2012 OECD Recommendation on the Governance of Clinical Trials and its explanatory memorandum can be found at www.oecd.org/sti/sci-tech/oecd-recommendation-governance-of-clinical-trials.pdf

See www.oecd.org/health

The Lancet 2012), The Global Burden of Disease Study 2010, December 13

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (NCPHSBBR) (1979), “The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research”

“The Nuremberg Code”(1949), Trials of War Criminals before the Nuremberg Military Tribunals Under Control Council Law No. 10, Vol. 2, pp. 181–182, US Government Printing Office, Washington

World Medical Association (WMA) (1964/2008), “The Declaration of Helsinki”

©OECD Observer No 294 Q1 2013




Economic data

E-Newsletter

Stay up-to-date with the latest news from the OECD by signing up for our e-newsletter :

Twitter feed

Editor's choice

  • Success story. Discover the story of this young Ethiopian woman who launched a successful business in the footwear industry and became a UN Goodwill Ambassador for Entrepreneurship.
  • Transports in Asia. The Asian Development Bank advocates sustainable transport in a continent where vehicle ownership is perceived as a sign of social success.
  • Vote for your favourite photograph! This World Bank #EachDayISee photo contest aims to display visual stories from all over the world through which people express what they would like to see changed and improved.
  • Why is investment so low in the euro area? This short IMF blog post gives you an insight into the causes of the euro-zone's drastic decline in investment.
  • Have your say! The UN wants to know what matters most to you: pick six global issues in the list and send it to the United Nations.
  • Clear air and healthy lungs: how to better tackle air pollution. From New Delhi to Accra, millions of people breathe polluted air. A new report examines the World Bank’s experience working to improve air quality.
  • The boring secret of great cities. Plenty of things make a city great but what really makes a difference originates in the structure of municipal government according to the OECD's report "The Metropolitan Century".
  • Guinea gets $37.7 million in extra IMF financing to help combat Ebola
  • Towards an international carbon pricing framework? Designing a unified international carbon pricing system could help to move towards a fully functional low-carbon global economy.
  • Putting the global economy on a more virtuous path. Current potential growth rates are well below pre-crisis levels. To avoid stagnation, governments have to put in place robust structural reforms.
  • World Water Day: 22 March 2015 For World Water Day, UN-Water identifies upcoming challenges and sets the theme for the years to come. In 2015, the theme for World Water Day is Water and Sustainable Development.
  • What drives street-based child labour?The ILO, UNICEF, Save the Children and the Lebanese Ministry of Labour launch a first-ever study assessing the scope and characteristics of the increasingly visible phenomenon of one of the worst forms of child labour.
  • No “Grexit”. Speaking to CNBC, OECD Secretary-General Angel Gurría says he would do everything to make sure Greece does not leave the euro. "Everybody wants Greece to stay in, everybody wants Greece to prosper and to get out of its short-term morass," he told CNBC. Watch the video.
  • engaging citizens
  • Interested in citizen engagement? The World Bank Group offers a four-week online course which aims to teach how citizens can engage in both policymaking and public service delivery.
  • 2.1 million jobs could be created in Europe by 2018 under the three-year investment plan put forward by European Commission President Jean-Claude Juncker, according to the ILO.
  • Become involved in urban flood risk management. This World Bank two-week online forum gives you the opportunity to discuss how to preserve cities from these natural disasters with experts and development leaders.
  • Promoting decent work for migrant workers.This ILO report highlights the need to ensure decent work for migrants, which is part of the global agenda on sustainable development.
  • Composite leading indicators

Most Popular Articles

Subscribe Now

<b>Subscribe now!</b>

To receive your exclusive print editions delivered to you directly


Online edition
Previous editions

Poll

What issue are you most concerned about in 2015?

Euro crisis
Unemployment
Global warming
International conflict
Other

OECD Insights Blog

NOTE: All signed articles in the OECD Observer express the opinions of the authors
and do not necessarily represent the official views of OECD member countries.

All rights reserved. OECD 2015